If the patient received a low maintenance dose of colistin, can therapy be restarted with a loading dose?

Yes, you can and should restart with a loading dose

If a patient received inadequate maintenance doses of colistin resulting in subtherapeutic levels, you should restart therapy with a full loading dose of 6-9 million IU (MIU), regardless of prior colistin exposure. This approach is critical because colistin has a long half-life (approximately 18.5 hours) and takes 2-3 days to reach steady-state concentrations without a loading dose, during which time the patient remains at subtherapeutic levels associated with higher mortality 1.

Pharmacokinetic Rationale

The fundamental issue is that colistin administered as colistimethate sodium (CMS) is an inactive prodrug that must convert to active colistin in vivo 1. When maintenance doses are inadequate or interrupted:

• Plasma colistin concentrations drop below therapeutic targets
• The long half-life means it takes 48-72 hours to rebuild adequate levels with maintenance dosing alone
• Suboptimal plasma concentrations during this period are directly associated with increased mortality 1

Studies demonstrate that even with standard maintenance dosing (3 MIU every 8 hours), patients had suboptimal concentrations for 2-3 days before reaching steady state 1. With low or interrupted maintenance doses, this problem is magnified.

Recommended Dosing Strategy

Loading Dose:

• 6-9 MIU of CMS as a single dose 1, 2, 1
• Administer regardless of renal function 1
• The 2022 guidelines specifically recommend 9 MIU loading dose 2

Maintenance Dosing (starting 12-24 hours after loading dose):

• 4.5 MIU every 12 hours for patients with CrCl >50 mL/min 1, 2, 1
• Adjust maintenance dose based on creatinine clearance using the formula: 2.5 mg × (1.5 × CrCl + 30) twice daily 2
• For patients on continuous renal replacement therapy: at least 9 MIU/day 1

Critical Clinical Considerations

Why the loading dose is essential in this scenario:

1. Time to therapeutic levels: Without a loading dose, you're condemning the patient to another 2-3 days of subtherapeutic exposure 1, 3

2. Mortality risk: The evidence clearly shows suboptimal colistin concentrations correlate with higher mortality in critically ill patients 1

3. Resistance development: Subtherapeutic levels promote resistance emergence, particularly concerning with already resistant organisms

4. No accumulation concern: The loading dose is designed to rapidly achieve target concentrations; previous low maintenance doses would have cleared given colistin's elimination kinetics

Safety profile with loading dose:

• The loading dose should be given even in renal dysfunction 1
• Nephrotoxicity is primarily related to cumulative exposure and maintenance dosing, not the loading dose 4, 5
• Studies show 20% incidence of acute kidney injury, but this is not specifically increased by loading doses 3
• The 2022 meta-analysis found loading doses associated with higher AKI, but this must be weighed against mortality benefit 5

Common Pitfalls to Avoid

1. Don't skip the loading dose thinking prior exposure is sufficient - if levels were low, prior exposure is irrelevant to current therapeutic needs

2. Don't reduce the loading dose in renal dysfunction - guidelines explicitly state loading dose should be given regardless of renal function 1

3. Don't start maintenance doses immediately - wait 12-24 hours after loading dose to avoid excessive accumulation 1

4. Don't forget to adjust maintenance doses for renal function - while loading dose is fixed, maintenance must be individualized 1, 2

5. Monitor renal function closely - check creatinine every 2-3 days and adjust maintenance dosing accordingly 2

Special Populations

For patients on CRRT: Give the full loading dose (6-9 MIU), then maintenance of at least 9 MIU/day without dose adjustment 1

For intermittent hemodialysis: Give normal loading dose, then 2 MIU every 12 hours, with dialysis performed toward the end of dosing interval 1

The evidence strongly supports restarting with a full loading dose when prior maintenance therapy was inadequate. The pharmacokinetic properties of colistin make this approach both necessary and safe when properly monitored.